In patients with intermediate-stage hepatocellular carcinoma (HKLC stage IIB), preoperative transarterial chemoembolization (TACE) significantly improves survival outcomes compared to upfront surgery alone. A study involving 154 matched patients found that the median overall survival for the TACE group undergoing surgical resection was 90.97 months, versus 30.68 months for the surgery-only group. Additionally, disease-free survival was also enhanced in those receiving TACE, indicating its potential as an effective neoadjuvant strategy.
Journal Article by Nandy K, Varty GP (…) Goel M et 6 al. in World J Surg
© 2024 International Society of Surgery/Société Internationale de Chirurgie (ISS/SIC).